Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 8/2009

01-08-2009 | Hepatobiliary and Pancreatic Tumors

Relationship Between Microvessel Count and Postoperative Survival in Patients with Intrahepatic Cholangiocarcinoma

Authors: Atsushi Nanashima, MD, Kenichiro Shibata, MD, Toshiyuki Nakayama, MD, Syuichi Tobinaga, MD, Masato Araki, MD, Masaki Kunizaki, MD, Hiroaki Takeshita, MD, Shigekazu Hidaka, MD, Terumitsu Sawai, MD, Takeshi Nagayasu, MD, Tsutomu Tagawa, MD

Published in: Annals of Surgical Oncology | Issue 8/2009

Login to get access

Abstract

Background

The present study aimed to elucidate the relationship between microvessel count (MVC) according to CD34 expression and prognosis in intrahepatic cholangiocarcinoma (ICC) patients who underwent hepatectomy based on our preliminary study.

Methods

Relationships between MVC and clinicopathological factors were examined in 37 ICC patients. CD34 expression was analyzed using immunohistochemical methods.

Results

Median MVC for ICC patients was 140/mm2, which was applied as a cutoff value. Lower MVC was significantly associated with larger tumor size, periductal infiltrating type, and advanced Japanese tumor–node–metastasis stage (p < 0.05). Univariate survival analysis identified higher carcinoembryonic antigen level, periductal infiltrating type, poor histological differentiation, and lower MVC as significantly associated with lower 5-year survival rates. The 5-year survival rate in the higher-MVC group was significantly greater than that in the lower-MVC group (44% vs. 7%, p = 0.048). According to Cox multivariate survival analysis, only periductal infiltrating type on macroscopic examination was identified as a significant independent risk factor for poor survival after hepatectomy (risk ratio 4.8; p = 0.006), not MVC (1.1; p = 0.82).

Conclusion

Tumor MVC might offer a useful prognostic marker of ICC patient survival after hepatectomy and further investigation in a larger series is warranted.
Literature
1.
Sano T, Shimada K, Sakamoto Y, Yamamoto J, Yamasaki S, Kosuge T. One hundred two consecutive hepatobiliary resections for perihilar cholangiocarcinoma with zero mortality. Ann Surg. 2006;244:240–7.PubMedCrossRef
2.
Kokudo N, Makuuchi M. Extent of resection and outcome after curative resection for intrahepatic cholangiocarcinoma. Surg Oncol Clin North Am. 2002;11:969–83.CrossRef
3.
Miwa S, Miyagawa S, Kobayashi A, et al. Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery. J Gastroenterol. 2006;41:893–900.PubMedCrossRef
4.
Kawarada Y, Yamagiwa K, Das BC. Analysis of the relationships between clinicopathologic factors and survival time in intrahepatic cholangiocarcinoma. Am J Surg. 2002;183:679–85.PubMedCrossRef
5.
Tamandl D, Herberger B, Gruenberger B, et al. Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2008;15:2787–94.PubMedCrossRef
6.
Muenphon K, Limpaiboon T, Jearanaikoon P, et al. Amplification of chromosome 21q22.3 harboring trefoil factor family genes in liver fluke related cholangiocarcinoma is associated with poor prognosis. World J Gastroenterol. 2006;12:4143–8.PubMed
7.
Park BK, Paik YH, Park JY, et al. The clinicopathologic significance of the expression of vascular endothelial growth factor-C in intrahepatic cholangiocarcinoma. Am J Clin Oncol. 2006;29:138–42.PubMedCrossRef
8.
Zhai B, Yan HX, Liu SQ, et al. Reduced expression of P120 catenin in cholangiocarcinoma correlated with tumor clinicopathologic parameters. World J Gastroenterol. 2008;14:3739–44.PubMedCrossRef
9.
Thuwajit P, Chawengrattanachot W, Thuwajit C, et al. Enhanced expression of mucin 6 glycoprotein in cholangiocarcinoma tissue from patients in Thailand as a prognostic marker for survival. J Gastroenterol Hepatol. 2008;23:771–8.PubMedCrossRef
10.
Itatsu K, Zen Y, Yamaguchi J, et al. Expression of matrix metalloproteinase 7 is an unfavorable postoperative prognostic factor in cholangiocarcinoma of the perihilar, hilar, and extrahepatic bile ducts. Hum Pathol. 2008;39:710–9.PubMedCrossRef
11.
Schmitz KJ, Lang H, Wohlschlaeger J, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for overall survival in intrahepatic cholangiocarcinoma. Virchows Arch. 2007;450:135–41.PubMedCrossRef
12.
Su MC, Hsu C, Kao HL, Jeng YM. CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma. Cancer Lett. 2006;235:34–9.PubMedCrossRef
13.
Nathan H, Aloia TA, Vauthey JN, et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2008;16(1):14–22.
14.
Cao Y. Molecular mechanisms and therapeutic development of angiogenesis inhibitors. Adv Cancer Res. 2008;100:113–31.PubMedCrossRef
15.
Yoshikawa D, Ojima H, Iwasaki M, et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer. 2008;98:418–25.PubMedCrossRef
16.
Shirabe K, Shimada M, Tsujita E, et al. Prognostic factors in node-negative intrahepatic cholangiocarcinoma with special reference to angiogenesis. Am J Surg. 2004;187:538–42.PubMedCrossRef
17.
Nanashima A, Yoshinaga M, Yamaguchi H, et al. An immunohistochemical study of tumor vascularity and proliferation activity in cholangiocellular carcinoma: relationship to clinicopathologic factors and prognosis after hepatic resection. Acta Med Nagasaki 2003;48;23–7.
18.
Jarnagin WR, Shoup M. Surgical management of cholangiocarcinoma. Semin Liver Dis. 2004;24:189–99.PubMedCrossRef
19.
Nanashima A, Sumida Y, Abo T, et al. Relationship between pattern of tumor enhancement and clinicopathologic characteristics in intrahepatic cholangiocarcinoma. J Surg Oncol. 2008;98:535–9.PubMedCrossRef
20.
Tang D, Nagano H, Yamamoto H, et al. Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance. Oncol Rep. 2006;15:525–32.PubMed
21.
Nanashima A, Yamaguchi H, Sawai T, et al. Prognostic factors in hepatic metastases of colorectal carcinoma: immunohistochemical analysis of tumor biological factors. Dig Dis Sci. 2001;46:1623–28.PubMedCrossRef
22.
Nanashima A, Nakayama T, Sumida Y, et al. Relationship between microvessel count and post-hepatectomy survival in patients with hepatocellular carcinoma. World J Gastroenterol. 2008;14:4915–22.PubMedCrossRef
23.
Nanashima A, Yamaguchi H, Shibasaki S, et al. Relationship between CT volumetry and functional liver volume using technetium-99 m galactosyl serum albumin scintigraphy in patients undergoing preoperative portal vein embolization before major hepatectomy: a preliminary study. Dig Dis Sci. 2006;51:1190–5.PubMedCrossRef
24.
Liver Cancer Study Group of Japan. Part I Clinical findings. In: Makuuchi M (editor) The general rules for the clinical and pathological study of primary liver cancer, 2nd English ed. Tokyo: Kanehara; 2003. p. 6–28.
25.
Nanashima A, Yano H, Yamaguchi H, et al. Immunohistochemical analysis of tumor biological factors in hepatocellular carcinoma: relationship to clinicopathological factors and prognosis after hepatic resection. J Gastroenterol. 2004;39:148–54.PubMedCrossRef
26.
Hai S, Kubo S, Yamamoto S, et al. Clinicopathologic characteristics of hepatitis C virus-associated intrahepatic cholangiocarcinoma. Dig Surg. 2005;22:432–9.PubMedCrossRef
27.
28.
Khan SA, Davidson BR, Goldin R, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut. 2002;51:1–9.CrossRef
29.
Park HS, Lee JM, Choi JY, et al. Preoperative evaluation of bile duct cancer: MRI combined with MR cholangiopancreatography versus MDCT with direct cholangiography. AJR Am J Roentgenol. 2008;190:396–405.PubMedCrossRef
30.
Valls C, Gumà A, Puig I, et al. Intrahepatic peripheral cholangiocarcinoma: CT evaluation. Abdom Imaging. 2000;25:490–6.PubMedCrossRef
31.
Kim SJ, Lee JM, Han JK, et al. Peripheral mass-forming cholangiocarcinoma in cirrhotic liver. AJR Am J Roentgenol. 2007;189:1428–34.PubMedCrossRef
32.
Seo S, Hatano E, Higashi T, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma. Surgery. 2008;143:769–77.PubMedCrossRef
33.
Wise C, Pilanthananond M, Perry BF, et al. Mechanisms of biliary carcinogenesis and growth. World J Gastroenterol. 2008;14:2986–89.PubMedCrossRef
34.
Burke D, Carnochan P, Glover C, et al. Correlation between tumour blood flow and fluorouracil distribution in a hypovascular liver metastasis model. Clin Exp Metastasis. 2000;18:617–22.PubMedCrossRef
35.
Miwa S, Soeda J, Miyagawa S. Interrelationship of platelet-derived endothelial cell growth factor, liver macrophages, and tumor microvessel density in patients with cholangiocellular carcinoma. Hepatogastroenterology. 2005;52:1398–402.PubMed
36.
Bergmann S, Pandolfi PP. Giving blood: a new role for CD40 in tumorigenesis. J Exp Med. 2006;203:2409–12.PubMedCrossRef
37.
Kozaka K, Sasaki M, Fujii T, et al. A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules: ‘bile ductular carcinoma’. Histopathology. 2007;51:390–400.PubMedCrossRef
38.
Sano T, Kamiya J, Nagino M, et al. Macroscopic classification and preoperative diagnosis of intrahepatic cholangiocarcinoma in Japan. J Hepatobiliary Pancreat Surg. 1999;6:101–7.PubMedCrossRef
Metadata
Title
Relationship Between Microvessel Count and Postoperative Survival in Patients with Intrahepatic Cholangiocarcinoma
Authors
Atsushi Nanashima, MD
Kenichiro Shibata, MD
Toshiyuki Nakayama, MD
Syuichi Tobinaga, MD
Masato Araki, MD
Masaki Kunizaki, MD
Hiroaki Takeshita, MD
Shigekazu Hidaka, MD
Terumitsu Sawai, MD
Takeshi Nagayasu, MD
Tsutomu Tagawa, MD
Publication date
01-08-2009
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 8/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0494-5

Other articles of this Issue 8/2009

Annals of Surgical Oncology 8/2009 Go to the issue

Hepatobiliary and Pancreatic Tumors

Evolving Treatment Strategies for Gallbladder Cancer

Breast Oncology

A Prospective, Multi-Institutional Study of Adjuvant Radiotherapy After Resection of Malignant Phyllodes Tumors

Gastrointestinal Oncology

Gallbladder Cancer: We Need to Do Better!

Melanomas

False-Negative Sentinel Node Biopsy

Endocrine Tumors

When Is Prophylactic Thyroidectomy Indicated for Patients with the RET Codon 609 Mutation?

Gastrointestinal Oncology

Sentinel Node Biopsy for the Individualization of Surgical Strategy for Cure of Early-Stage Colon Cancer